Conference Coverage

It’s time to put to rest the calcium supplement controversy


 

EXPERT ANALYSIS FROM THE NATURAL SUPPLEMENTS UPDATE

"We hope our case study puts to rest these concerns about calcium supplements so we cover our bones as well as not worry about cardiovascular effects," Dr. Weaver concluded. "Adequate intake of calcium should be below the tolerable upper limit and should be encouraged for bone health. Most dietary guidance committees recommend foods as the first choice, but supplements should be used to fill dietary shortcomings. So if the dietary guidelines recommend 3 cups/day of low-fat dairy product equivalents to get enough calcium, the addition of a 300-mg calcium supplement is recommended for every one serving missed."

"Bone health is a lifelong concern," she said. "Peak skeletal mass is achieved by ages 20-30 and the adult skeleton is remodeled and replaced every 10 years."

Milk contains enough calcium to meet dietary recommendations, but milk consumption is decreasing among Americans in all age groups, especially in children, she said. "This decline could set them up to grow lower levels of bone mass. Over life, that could position them to be in a fracture zone earlier. So we have to be concerned: How do we get these minerals needed if use of the main dietary source – milk – is declining? The controversy of calcium supplements comes to the forefront, because that is one alternative to milk. There are not that many foods that are concentrated in well-absorbed calcium."

Dr. Weaver disclosed that she serves on the boards of the National Osteoporosis Foundation, the International Life Sciences Institute, Showalter, and Pharmavite. She has also received grant support from the National Institutes of Health, the Dairy Research Institute, Nestle, and Tate & Lyle.

dbrunk@frontlinemedcom.com

Pages

Recommended Reading

Maternal lupus doubled autism risk
MDedge ObGyn
Naltrexone, hyperbaric oxygen show promise for fibromyalgia
MDedge ObGyn
Exercise dampens aromatase inhibitor–related joint pain
MDedge ObGyn
No survival benefit to bisphosphonate in chemoresistant breast cancer
MDedge ObGyn
FDA: Stop prescribing combo drugs with high-dose acetaminophen
MDedge ObGyn
FDA: Naproxen may pose lower CV risk
MDedge ObGyn
Shift in approach needed for managing inflammatory arthritis in pregnancy
MDedge ObGyn
NSAID makers argue against new warnings on CV risks
MDedge ObGyn
No new cardiovascular warnings needed for NSAIDs say FDA advisers
MDedge ObGyn
Antiphospholipid, thrombosis histories differently affect pregnancy antithrombotic needs
MDedge ObGyn